Healwell AI’s Enterprise Pivot: From Episodic to Recurring, with a Fortress Balance Sheet
Q2 2026 shows the trough of a transition: recurring revenue growth, a 10% EBITDA target, and a SpaceX-backed balance sheet.
AIDX.TO · Earnings Call · 2026-08-07
Quarter in Context
Healwell AI reported Q2 2026 revenue of C$33M, flat year-over-year, but the composition tells a story. The quarter marks the end of a difficult integration period following the Orion Health acquisition. As CEO James Lee put it, “We are through the difficult part of integration and transition, and we are now seeing the benefit of the enterprise healthcare focus.” — James Lee, Chief Executive Officer · 2026-08-07 The company is shifting from episodic life science projects to higher-margin recurring enterprise sales, a theme that dominates the call. Enterprise sales are now the primary go-to-market strategy. The first half of 2026 revenue grew 60% to C$66.2M, driven by Orion, and the company generated C$4.5M of positive operating cash flow, a 145% improvement. CFO Anthony Lam noted, “We generated $4.5 million of positive operating cash flow for the first half of 2026, a $14.4 million improvement, approximately 145% compared to cash used in the prior year period.” — Anthony Lam, Chief Financial Officer · 2026-08-07 This cash flow inflection is central to the balance sheet story, which now includes an indirect stake in SpaceX valued at approximately C$23M, up from a carrying value of C$4.6M.The Enterprise Pivot
The transition has produced what management calls four growth engines, all built on the same platform: HIE and clinical data unlock, SMARTSuite, global life science enterprise business, and consented data via WELLTRUST. These engines are shifting the revenue profile from lumpy project work to multiyear licenses with AI product deployments. The company reports that AI data output overtook human output for the first time in May, and 1,291 physicians have been onboarded to AI copilots. Analyst skepticism centered on a sequential decline in AI-related subscription revenue. Management attributed it to the divestiture of Mutuo and to revenue recognition timing on enterprise licenses. CEO James Lee explained, “When you're delivering on enterprise licenses, the revenue recognition is very different from the sales that we've made. So we've announced sales in the Middle East, in Canada and the U.S., and we're in the process of delivering those. So we'll be able to recognize revenue against those as those delivery milestones are made in the third and fourth quarter.” — James Lee, Chief Executive Officer · 2026-08-07 This was a recurring theme across calls; a year ago, management had said it was too early for cross-sells, but now the pipeline is maturing. “There have been no cross-sells that's too early. The business has only been going 3 months and the RFP process from RFPs are closed implementation, as you can imagine, is well longer than a 3-month process.” — James Lee, CEO · 2025-08-13 That commentary from the November 2025 call now reads as a precursor to the current push. The insurance opportunity was another focus. Management sees it as a larger, slower-burn market but with significant upside. “What I would say is they are larger but slower burn sales. So we won't be expecting to make any of those in 2026. But the sheer size of that market is what we're excited about, Michael.” — James Lee, Chief Executive Officer · 2026-08-07 The company also emphasized public sector tailwinds and partnerships with major systems integrators.Balance Sheet and Optionality
On the balance sheet, the SpaceX holding provides optionality. Management indicated it plans to liquidate the position as practical, and the cash flow improvement reduces reliance on external capital. The company remains on track for its 10% adjusted EBITDA margin target by year-end, though it acknowledged that AI and data science growth will land at the lower end of the 30-50% range, with revenue recognition in the second half.Outlook and Risks
Ultimately, Healwell is repositioning itself as a recurring, enterprise-focused healthcare AI company. The quarter’s flat revenue masks the underlying shift, but the cash flow and pipeline suggest the transition is working. The key risk is execution on revenue recognition and the sales cycle elongation, but the balance sheet provides a cushion.We are through the difficult part of integration and transition, and we are now seeing the benefit of the enterprise healthcare focus. We have successfully demonstrated an upsell of customers with our AI capability. We've integrated our business lines, and we have improved our balance sheet.